Could an immune drug ease schizophrenia symptoms?

NCT ID NCT07680946

Recruiting now Disease control Sponsor: TG Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether ublituximab, an immune-modulating drug, can reduce symptoms in people with treatment-resistant schizophrenia. Participants receive the drug by IV infusion, and researchers measure changes in symptom scores over time. The goal is to see if targeting the immune system might help when standard antipsychotics fail.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ublituximab (also known as BRIUMVI)
What this could lead to: If successful, this could point toward a new treatment option for people with schizophrenia who do not respond to standard antipsychotics.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause infusion reactions or infections, and its effect on schizophrenia symptoms is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

TG Therapeutics Investigational Trial Site
RECRUITING

Little Rock, Arkansas, 72204, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Richardson, Texas, 75080, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.